In this study, we demonstrated that deZP for pharmacopuncture reduced IL-1β levels and suggested that this effect may be mediated by the NLRP3 inflammasome signal pathway in a gouty arthritis mouse model. This evidence concerns the gene IL1B and arthritic joint disease.